ArticleAmerican journal of ophthalmology case reports2026
Visually significant corneal deposits associated with rifabutin therapy for
Article in American journal of ophthalmology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To report the clinical and histopathological features of a case of visually significant corneal deposits due to rifabutin therapy used to treat Observations: A 73-year-old male with a history of recurrent bartonellosis on rifabutin therapy presented with glare and haloes in both eyes. Slit lamp examination showed pigmented corneal deposits, higher in density and larger in size in the periphery than the center. Rifabutin was discontinued, but the corneal deposits and visual symptoms persisted more than one year later. The patient underwent a penetrating keratoplasty of the left eye. Histopathologic evaluation of the cornea revealed focal tan-golden round/granular-like deposits in the deep corneal stroma and in rare endothelial cells. There was no evidence of inflammation. Conclusions and importance: This case illustrates the histopathologic features of rifabutin-induced corneal deposits, providing novel insights about the pathophysiology of these deposits. Clinicians should be aware that rifabutin is a potential treatment for bartonellosis, and that rifabutin can cause visually significant corneal deposits. Multidisciplinary management is crucial for patients with corneal deposits associated with rifabutin therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.